Presentation is loading. Please wait.

Presentation is loading. Please wait.

One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.

Published byGeoffrey Parker Modified over 8 years ago

Similar presentations

Presentation on theme: "One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart."— Presentation transcript:

1 One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart Center, Leipzig, Germany Sabine Bleiziffer German Heart Center, Munich, Germany Johan Bosmans University Hospital Antwerp, Antwerp, Belgium Ulrich Gerckens Gemeinschaftskrankenhaus Bonn, Bonn, Germany Peter Wenaweser University Hospital Bern, Bern, Switzerland Stephen Brecker St. George’s Hospital, London, United Kingdom Corrado Tamburino Ferrarotto Hospital, University of Catania, Catania, Italy (on behalf of the ADVANCE Investigators) UC201403656 EE

2 Disclosure Statement of Financial Interest Grant/Research Support Grant/Research Support Consulting Fees/Honoraria Consulting Fees/Honoraria Major Stock Shareholder/Equity Major Stock Shareholder/Equity Royalty Income Royalty Income Ownership/Founder Ownership/Founder Intellectual Property Rights Intellectual Property Rights Other Financial Benefit Other Financial Benefit Medtronic, Inc. Medtronic, Inc. Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company

3 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. Transcatheter aortic valve implant (TAVI) enables treatment of aortic valve stenosis without open-heart surgery. The CoreValve ADVANCE study evaluated the clinical benefits of TAVI using the CoreValve system in a fully monitored, “real world” trial. This presentation reports for the first time the complete 1-year patient outcomes from the ADVANCE study. CoreValve ADVANCE | Background

4 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. Medtronic CoreValve ® System Porcine pericardial tissue valve sutured to a self expanding nitinol frame Supra-annular valve position preserves circularity at level of valve function 18F catheter delivery system, with AccuTrak ® Stability Layer available in later cases 2 valve sizes were used in this study: 26 mm and 29 mm CoreValve ADVANCE | Background

5 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. 1,015 patients enrolled from March 2010 to July 2011 –5 year follow-up 44 centres - 12 countries in Western Europe, Asia and South America All centres had conducted at least 40 TAVI procedures prior to the study and had a Heart Team in place Clinical endpoints reported according to VARC As-treated analysis CoreValve ADVANCE | Methods

6 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | Endpoints Primary Endpoint- Major Adverse Cardiac & Cerebrovascular Events (MACCE) at 30-days post procedure MACCE defined as a composite of All cause mortality Myocardial Infarction (Q-wave and non-Q-wave) Emergent Cardiac Surgery or Percutaneous Re-intervention Stroke Additional Clinical Endpoints (VARC) Cardiovascular Mortality Bleeding Vascular Complications Acute Kidney Injury New Pacemaker Implantation

7 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | Study Oversight 100% of all Patients were monitored All Primary Endpoint events adjudicated by an Independent clinical events committee consisting of TAVI-experienced interventional cardiologists and cardiac surgeons using VARC I definitions All cerebrovascular events adjudicated by an independent neurologist Adjudication of events utilized all available relevant source documents; including neuroimaging and systematic NIH Stroke Scale assessments Core laboratory for systematic review and assessment of EKGs and procedure angiograms Site reported echocardiographic data

8 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | Baseline Characteristics

9 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. *measured by angiography CoreValve ADVANCE | Procedural Results

10 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. *Kaplan-Meier Estimates CoreValve ADVANCE | Primary Endpoint

11 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | 1-Year Stroke

12 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. *Kaplan-Meier Estimates †New AKI that occurred outside of the 72 hr post-TAVI window are included CoreValve ADVANCE | Additional VARC I Endpoints

13 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | 1-Year Survival

14 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | Survival by Logistic EuroSCORE

15 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | NYHA Symptom Status

16 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | Valve Performance

17 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | Aortic Regurgitation

18 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | Paravalvular Leak

19 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | Transvalvular Regurgitation

20 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. *At discharge CoreValve ADVANCE | Survival by AR*

21

22 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | 2-Year Survival

23 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. Medtronic CoreValve ADVANCE is one of the largest “real world” TAVI trials performed in multiple experienced centres. 1-year outcomes demonstrate –low stroke rates at 1-year –low rates of AR and PVL at 1-year –mild AR with the same low mortality rate as those patients with no AR –improved valve performance 2-year patient survival rates continues to remain high CoreValve ADVANCE | Summary and Conclusions

24 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. Non destiné au marché français. ©Medtronic, Inc. 2013. All Rights Reserved. Thank You CoreValve ADVANCE Study Centers CoreValve is a registered trademark of Medtronic CV Luxembourg S.a.r.l. © 2013.

Download ppt "One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart."

Similar presentations

Thirty-day Outcomes from the Multi-centre European Pivotal Trial for Transapical Transcatheter Aortic Valve Implantation with a Self-expanding Prosthesis.

Thirty-day Outcomes from the Multi-centre European Pivotal Trial for Transapical Transcatheter Aortic Valve Implantation with a Self-expanding Prosthesis.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve ® has been approved. The CoreValve ® System is not currently approved in the USA,

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve ® has been approved. The CoreValve ® System is not currently approved in the USA,
INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. ©Medtronic, Inc. 2013. All.

INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA or Japan. ©Medtronic, Inc All.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. The information in.

INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. The information in.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2012.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Stephen Brecker St. George’s Hospital, London, United Kingdom S Mealing, J Eaton, M Sculpher Oxford Outcomes (ICON), Oxford, United Kingdom Johan Bosmans.

Stephen Brecker St. George’s Hospital, London, United Kingdom S Mealing, J Eaton, M Sculpher Oxford Outcomes (ICON), Oxford, United Kingdom Johan Bosmans.
When Does Baseline Left Ventricular Function Influence Survival Post Transcatheter Aortic Valve Implantation? —The CoreValve Australia New Zealand Study.

When Does Baseline Left Ventricular Function Influence Survival Post Transcatheter Aortic Valve Implantation? —The CoreValve Australia New Zealand Study.
Georg Nickenig, Universitatsklinikum Bonn, Germany Jan-Malte Sinning, Universitatsklinikum Bonn, Germany Jan Kovac, Glenfield Hospital, Leicester, UK Peter.

Georg Nickenig, Universitatsklinikum Bonn, Germany Jan-Malte Sinning, Universitatsklinikum Bonn, Germany Jan Kovac, Glenfield Hospital, Leicester, UK Peter.
Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.

Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.
ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.

ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
6-Month Outcomes Following Transcatheter Aortic Valve Implantation With a Novel Repositionable Self-Expanding Bioprosthesis Ian T. Meredith, MBBS, PhD,

6-Month Outcomes Following Transcatheter Aortic Valve Implantation With a Novel Repositionable Self-Expanding Bioprosthesis Ian T. Meredith, MBBS, PhD,
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Compared with Surgical Aortic Valve Replacement in High Risk.

Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Compared with Surgical Aortic Valve Replacement in High Risk.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.

Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
University Heart Center Hamburg

University Heart Center Hamburg
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.

The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
Template Title Speaker Name Subtitle. Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity.

Template Title Speaker Name Subtitle. Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Similar presentations

Ads by Google